ArticleFrontiers in immunology2026
Targeting the ISG15+STAT1+ monocyte-driven inflammatory storm with Fedratinib in traumatic lung injury via the JAK2/STAT3/PIM1 axis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Traumatic lung injury (TLI) frequently progresses to acute respiratory distress syndrome (ARDS), a condition with high mortality and limited targeted therapies. This study aimed to identify specific immune cell drivers and potential therapeutic targets for precision intervention in TLI. Methods: We conducted a comprehensive analysis of single-cell RNA sequencing (scRNA-seq) data from peripheral blood mononuclear cells of trauma patients, transcriptomic data from alveolar macrophages in ARDS patients, and lung tissue transcriptomic data from a TLI mouse model. An integrated bioinformatics approach was employed, including the use of the Augur and Milo algorithms for prioritizing cellular perturbations, Monocle 3 for trajectory inference, and two-sample Mendelian randomization (TSMR) for causal inference. Potential drugs were screened using Connectivity Map, target-specificity predictions were made using the scRANK algorithm, and validation was performed using an Results: The scRNA-seq analyses revealed that classical monocytes showed the greatest disturbance and response following trauma. Among these, the ISG15+STAT1+ monocyte subpopulation expanded post-trauma and drove an inflammatory storm through robust M1-like polarization. PIM1 was identified as a core pathogenic gene co-upregulated in both peripheral blood and lung tissue. Further TSMR analysis confirmed elevated PIM1 expression as a causal risk factor for ARDS. Concurrently, the JAK2/STAT3/PIM1 pathway is activated synchronously during the acute trauma phase. Drug repurposing research suggests that the JAK2 inhibitor Fedratinib can reverse the transcriptomic characteristics of TLI. Conclusions: This study identifies the JAK2/STAT3/PIM1 signaling axis within the ISG15+STAT1+ monocyte subpopulation as a key driver of TLI and a potential therapeutic target, and suggests that fedratinib is a potential candidate for the targeted treatment of TLI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.